Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Income from Continuing Operations (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Income from Continuing Operations for 15 consecutive years, with 4132000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 42.44% to 4132000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 17382000.0, a 103.3% increase, with the full-year FY2025 number at 17382000.0, up 103.3% from a year prior.
  • Income from Continuing Operations was 4132000.0 for Q4 2025 at Niagen Bioscience, down from 4578000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 7179000.0 in Q4 2024 to a low of 8856000.0 in Q3 2021.
  • A 5-year average of 1248800.0 and a median of 1201500.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: plummeted 111.06% in 2021, then surged 24160.0% in 2025.
  • Niagen Bioscience's Income from Continuing Operations stood at 5325000.0 in 2021, then soared by 72.88% to 1444000.0 in 2022, then soared by 107.89% to 114000.0 in 2023, then soared by 6197.37% to 7179000.0 in 2024, then crashed by 42.44% to 4132000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Income from Continuing Operations are 4132000.0 (Q4 2025), 4578000.0 (Q3 2025), and 3609000.0 (Q2 2025).